Sundhar Ramalingam

2.0k total citations
25 papers, 684 citations indexed

About

Sundhar Ramalingam is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Sundhar Ramalingam has authored 25 papers receiving a total of 684 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in Sundhar Ramalingam's work include Cancer Immunotherapy and Biomarkers (9 papers), Prostate Cancer Treatment and Research (8 papers) and Radiopharmaceutical Chemistry and Applications (5 papers). Sundhar Ramalingam is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), Prostate Cancer Treatment and Research (8 papers) and Radiopharmaceutical Chemistry and Applications (5 papers). Sundhar Ramalingam collaborates with scholars based in United States, Japan and Singapore. Sundhar Ramalingam's co-authors include Michael R. Harrison, Satoshi Nishizuka, Brett Spurrier, Brant A. Inman, Thomas A. Longo, Daniel J. George, Tian Zhang, Andrew J. Armstrong, Yuan Wu and Patrick Healy and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Sundhar Ramalingam

25 papers receiving 679 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sundhar Ramalingam United States 12 296 287 199 161 100 25 684
Haizhen Lu China 13 264 0.9× 231 0.8× 145 0.7× 113 0.7× 45 0.5× 47 687
Stephan Tschirdewahn Germany 16 234 0.8× 197 0.7× 269 1.4× 174 1.1× 54 0.5× 57 677
János Fillinger Hungary 15 283 1.0× 427 1.5× 212 1.1× 102 0.6× 57 0.6× 46 701
Rajiv Dua United Kingdom 10 161 0.5× 242 0.8× 110 0.6× 142 0.9× 29 0.3× 14 582
Giuseppe Gullo Ireland 13 271 0.9× 368 1.3× 151 0.8× 59 0.4× 41 0.4× 42 692
Germana Tognon Italy 18 264 0.9× 333 1.2× 152 0.8× 183 1.1× 90 0.9× 38 1.2k
Sahar Al‐Haddad Canada 9 233 0.8× 216 0.8× 220 1.1× 84 0.5× 31 0.3× 14 609
Sophia L. Maund United States 13 368 1.2× 360 1.3× 222 1.1× 83 0.5× 77 0.8× 31 815
Hideaki Mabuchi Japan 17 383 1.3× 290 1.0× 433 2.2× 280 1.7× 262 2.6× 33 1.1k
Jones T. Nauseef United States 9 209 0.7× 283 1.0× 256 1.3× 37 0.2× 40 0.4× 49 630

Countries citing papers authored by Sundhar Ramalingam

Since Specialization
Citations

This map shows the geographic impact of Sundhar Ramalingam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sundhar Ramalingam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sundhar Ramalingam more than expected).

Fields of papers citing papers by Sundhar Ramalingam

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sundhar Ramalingam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sundhar Ramalingam. The network helps show where Sundhar Ramalingam may publish in the future.

Co-authorship network of co-authors of Sundhar Ramalingam

This figure shows the co-authorship network connecting the top 25 collaborators of Sundhar Ramalingam. A scholar is included among the top collaborators of Sundhar Ramalingam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sundhar Ramalingam. Sundhar Ramalingam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Howard, Lauren E., Bridget F. Koontz, Scott T. Tagawa, et al.. (2024). Intensifying Salvage Therapy in Prostate-specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy with Apalutamide, Salvage Radiation, and Docetaxel: The Phase 2 STARTAR Trial. European Urology Oncology. 8(2). 287–295. 1 indexed citations
2.
George, Daniel J., et al.. (2023). Clear Cell Renal Cell Carcinoma: From Biology to Treatment. Cancers. 15(3). 665–665. 47 indexed citations
3.
Clarke, Jeffrey, Xiaofei F. Wang, Thomas E. Stinchcombe, et al.. (2022). A Phase 2 Clinical Trial of Combination Nivolumab, Ipilimumab, and Paclitaxel in Patients With Untreated Metastatic NSCLC: The OPTIMAL Trial. JTO Clinical and Research Reports. 3(6). 100337–100337. 1 indexed citations
4.
Rose, Tracy L., Michael R. Harrison, Allison M. Deal, et al.. (2021). Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. Journal of Clinical Oncology. 39(28). 3140–3148. 93 indexed citations
5.
Rose, Tracy L., Michael R. Harrison, Allison M. Deal, et al.. (2021). Phase II study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy prior to radical cystectomy (RC) in patients with muscle-invasive bladder cancer (MIBC).. Journal of Clinical Oncology. 39(6_suppl). 396–396. 7 indexed citations
6.
Brown, Landon C., Kunal Desai, Chester Kao, et al.. (2020). A multicenter retrospective study to evaluate real-world clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) and brain metastasis treated with ipilimumab and nivolumab.. Journal of Clinical Oncology. 38(6_suppl). 637–637. 3 indexed citations
7.
Tucker, Matthew D., Jason Zhu, Daniele Marin, et al.. (2019). Pembrolizumab in men with heavily treated metastatic castrate‐resistant prostate cancer. Cancer Medicine. 8(10). 4644–4655. 59 indexed citations
8.
Ramalingam, Sundhar, Daniel J. George, & Michael R. Harrison. (2018). How we treat brain metastases in metastatic renal cell carcinoma.. PubMed. 16(2). 110–114. 6 indexed citations
9.
Ramalingam, Sundhar, Michael Humeniuk, Julia Rasmussen, et al.. (2017). Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate–resistant prostate cancer. Urologic Oncology Seminars and Original Investigations. 35(6). 418–424. 20 indexed citations
10.
Humeniuk, Michael, Rajan T. Gupta, Patrick Healy, et al.. (2017). Platinum sensitivity in metastatic prostate cancer: does histology matter?. Prostate Cancer and Prostatic Diseases. 21(1). 92–99. 16 indexed citations
11.
Ramalingam, Sundhar, Michaela A. Dinan, & Jeffrey Crawford. (2017). 4B.02 Increasing Survival in Stage IV NSCLC in Academic versus Community Based Centers in the National Cancer Database. Journal of Thoracic Oncology. 12(11). S1560–S1560. 1 indexed citations
12.
Inman, Brant A., Thomas A. Longo, Sundhar Ramalingam, & Michael R. Harrison. (2016). Atezolizumab: A PD-L1–Blocking Antibody for Bladder Cancer. Clinical Cancer Research. 23(8). 1886–1890. 187 indexed citations
13.
Glass, Oliver, Sundhar Ramalingam, & Michael R. Harrison. (2016). Resistance exercise training in patients with genitourinary cancers to mitigate treatment-related skeletal muscle loss.. PubMed. 14(6). 436–46. 5 indexed citations
14.
Ramalingam, Sundhar, et al.. (2016). Treatment‐related neuroendocrine prostate cancer resulting in Cushing's syndrome. International Journal of Urology. 23(12). 1038–1041. 12 indexed citations
15.
Ramalingam, Sundhar, Kathryn I. Pollak, Leah L. Zullig, & Michael R. Harrison. (2015). What Should We Tell Patients About Physical Activity After a Prostate Cancer Diagnosis?. PubMed. 29(9). 680–5, 687. 1 indexed citations
16.
Clegg, Hilary V., Yoko Itahana, Koji Itahana, Sundhar Ramalingam, & Yanping Zhang. (2012). Mdm2 RING Mutation Enhances p53 Transcriptional Activity and p53-p300 Interaction. PLoS ONE. 7(5). e38212–e38212. 12 indexed citations
17.
Spurrier, Brett, Sundhar Ramalingam, & Satoshi Nishizuka. (2008). Reverse-phase protein lysate microarrays for cell signaling analysis. Nature Protocols. 3(11). 1796–1808. 140 indexed citations
18.
Nishizuka, Satoshi, Sundhar Ramalingam, Brett Spurrier, et al.. (2008). Quantitative Protein Network Monitoring in Response to DNA Damage. Journal of Proteome Research. 7(2). 803–808. 15 indexed citations
19.
Ramalingam, Sundhar, Lynn Young, Tsutomu Shimura, et al.. (2007). Quantitative Assessment of the p53-Mdm2 Feedback Loop Using Protein Lysate Microarrays. Cancer Research. 67(13). 6247–6252. 31 indexed citations
20.
Spurrier, Brett, et al.. (2007). Antibody screening database for protein kinetic modeling. PROTEOMICS. 7(18). 3259–3263. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Haizhen Lu Breakdown of academic impact, for papers by Stephan Tschirdewahn Breakdown of academic impact, for papers by János Fillinger Breakdown of academic impact, for papers by Rajiv Dua Breakdown of academic impact, for papers by Giuseppe Gullo Breakdown of academic impact, for papers by Germana Tognon Breakdown of academic impact, for papers by Sahar Al‐Haddad Breakdown of academic impact, for papers by Sophia L. Maund Breakdown of academic impact, for papers by Hideaki Mabuchi Breakdown of academic impact, for papers by Jones T. Nauseef
Rankless by CCL
2026